ImageVerifierCode 换一换
格式:PPT , 页数:26 ,大小:1.80MB ,
资源ID:378961      下载积分:2000 积分
快捷下载
登录下载
邮箱/手机:
温馨提示:
如需开发票,请勿充值!快捷下载时,用户名和密码都是您填写的邮箱或者手机号,方便查询和重复下载(系统自动生成)。
如填写123,账号就是123,密码也是123。
特别说明:
请自助下载,系统不会自动发送文件的哦; 如果您已付费,想二次下载,请登录后访问:我的下载记录
支付方式: 支付宝扫码支付 微信扫码支付   
注意:如需开发票,请勿充值!
验证码:   换一换

加入VIP,免费下载
 

温馨提示:由于个人手机设置不同,如果发现不能下载,请复制以下地址【http://www.mydoc123.com/d-378961.html】到电脑端继续下载(重复下载不扣费)。

已注册用户请登录:
账号:
密码:
验证码:   换一换
  忘记密码?
三方登录: 微信登录  

下载须知

1: 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。
2: 试题试卷类文档,如果标题没有明确说明有答案则都视为没有答案,请知晓。
3: 文件的所有权益归上传用户所有。
4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
5. 本站仅提供交流平台,并不能对任何下载内容负责。
6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。

版权提示 | 免责声明

本文(Biochemical Targets for Antifungal Chemotherapy.ppt)为本站会员(王申宇)主动上传,麦多课文库仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对上载内容本身不做任何修改或编辑。 若此文所含内容侵犯了您的版权或隐私,请立即通知麦多课文库(发送邮件至master@mydoc123.com或直接QQ联系客服),我们立即给予删除!

Biochemical Targets for Antifungal Chemotherapy.ppt

1、Biochemical Targets for Antifungal Chemotherapy,Fungal cells are complex organisms that share many biochemical targets with other eukaryotic cells. Therefore, agents that interact with fungal targets not found in eukaryotic cells are needed. The fungal cell wall is a unique organelle that fulfills

2、the criteria for selective toxicity. Fungal cell wall differs greatly from bacterial cell wall. Therefore, fungi are unaffected by antibacterial cell wall inhibitors such as -lactams and vancomycin.,FIBRILLAR LAYER MANNOPROTEIN -GLUCAN -GLUCAN, CHITIN MANNOPROTEIN PLASMA MEMBRANE,Arrangement of the

3、biomolecular components of the cell wall accounts for the individual identity of the organism. Although, each organism has a different biochemical composition, their gross cell wall structure is similar.Antifungal agents targeted towards:Inhibition of fungal cell wall synthesis caspofungin is a -glu

4、can synthesis inhibitor; several more compounds are under investigationInhibition of fungal cell membrane synthesis ergosterol is the target (cell membranes of fungi and mammals contain different sterols): polyenes, azoles, triazoles, alkylaminesInhibition of cell division microtubule effects: grise

5、ofulvin; DNA: flucytosine.,Biochemical Targets for Antifungal Chemotherapy,Antifungal Agents- Sites of action,Echinocandins Inhibit fungal cell wall biosynthesis,Griseofulvin Inhibits mitotic spindle formation,Antifungal Agents Unless indicated all are on the UW formulary,1. Polyene Antifungal Drugs

6、These drugs interact with ergosterol in the fungal cell membrane and form pores Polyenes are related chemically to the macrolide antibiotics with the large lactone ring but have the distinctive characteristic of conjugated double bonds and a lipophilic (a chromophore of 4-7 conjugated double bonds)

7、and hyrophilic side (several alcohols, acids and usually a sugar). The number of conjugated double bonds correlates directly with antifungal activity in vitro and inversely with the degree of toxicity to mammalian cells. They are unstable, only slightly soluble, and poorly absorbed when taken orally

8、Amphotericin BNystatin (Natamycin) Pimaricin,Mechanism of Action of Polyenes,Polyenes bind to fungal membrane sterols. The selective effect is achieved because the sterol in highest concentration is ergosterol and polyenes have a high affinity for ergosterol. They insert into the membrane and disru

9、pt membrane function. The membranes become leaky. Ergosterol is not present in mammalian membranes. Recent thinking is that the polyenes form small transmembrane pores that allow K to leak through. See figure next slide. The polyenes are fungicidal at high concentrations.,cholesterol,ergosterol,Mech

10、anism of Action of Polyenes,Amphotericin B, a polyene antibiotic, is produced by Streptomyces nodosus. Discovered in 1956 has been for 30 years the main available drug to control serious fungal infections. Amp. B is indicated for treatment of severe, potentially life threatening fungal infections.,U

11、nfortunately, it must be given IV and is toxic (due to nonselective action on cholesterol in mammalian cell membranes). Serious fungal infections involve long therapy. Resistance is due to lower production of membrane sterols or altered sterols, but is relatively rare at present. Target modification

12、 and reduced access to target are other mechanisms of resistance.,Amphotericin B,Amphotericin B,DispositionAmp. B is not absorbed orally. It is given as a colloidal dispersion by slow IV infusion. It is highly bound to cholesterol-lipoprotein and has a plasma T1/2 of about 1 day and 1-2 weeks from t

13、issues. It is excreted in urine over a long time. Penetration into the CNS is poor. However, for fungal infections of the CNS, amphotericin B is mixed with cerebrospinal fluid (CSF) that is obtained from a spinal tap. The solution of amphotericin is then reinjected through the tap.,Amphotericin B,Ad

14、verse Effects: Reactions on infusion - headache, fever, chills, anorexia, vomiting, muscle and joint pain. Pain at site of injection and thrombophlebitis are frequent complications of intravenous administration. Drug must never be given intramuscular. Can give aspirin, meperidine, steroids, antiemet

15、ics etc to prevent some of these.Nephrotoxicity - chronic renal tox in up to 80% of patients taking the drug for prolonged periods. It is reversible but can be irreversible in high doses. Test for kidney function regularly. This is the most common limiting toxicity of the drug.Hematologic - hemolyti

16、c anemia due to effects on RBC membrane.Other less common reactions - cardiac, convulsions, neuropathy, hearing loss, allergic, etc.Some decrease in adverse effects particularly nephrotoxicity with liposomal preparations; the idea with the lipid preps is to decrease nonspecific binding to mammalian

17、membranes.,Products: Amphotericin B. (Fungizone ) 50 mg/vial with 41mg of sodium deoxycholate. Reconstitute with water. Give a test dose and gradually increase dose. Dont exceed 1.5mg/kg/d. Alternate day therapy is sometimes used. Several months of therapy is usually needed.Abelcet (Liposome Co.) 1:

18、1 mixture of amphotericin and lipid complex, 100 mg/20 ml. Rationale for this lipid preparation is that amphotericin B should have a greater affinity for the lipid vehicle than for cholesterol in cell membranes, thus lower toxicity. Lipid associated amphotericin B is drawn into the reticuloendotheli

19、al system, concentrating in lymphatic tissues, spleen, liver and lungs where infectious fungi concentrate. Lipases excreted from fungi release drug from lipid carrier allowing to bind to ergosterol in fungal cell membranes to exert fungistatic and fungicidal activities.Aphotec (Sequus Pharmaceutical

20、s) cholesteryl colloidal dispersion, 50 or 100 mg/20 ml (not on UW formulary) Supplied in variety of topical forms including a 3% cream, lotion or ointment and 100mg/mL oral suspension to treat cutaneous and mucocutaneous mycoses caused by Candida albicans AmBiosome (Fujisawa) liposomal, 50mg/vial.,

21、Nystatin Isolated from streptomyces noursei in 1951. A conjugated tetraene, is the first clinically useful polyene antifungal antibiotic. Available in oral tablets, powder for suspension, vaginal tablets, pastilles. This polyene is used for local therapy only (not absorbed). For gut Candidiasis, and

22、 in a “swish and swallow“ routine for oral Candidiasis.,Nystatin,No significant adverse effects with these uses. Combined with tetracycline to prevent monilial overgrowth caused by the destruction of bacterial microflora of the intestine during tetracycline therapy.(Mycostatin and other generic prod

23、ucts),Natamycin (Pimaricin; Natacyn)Polyene antibiotic obtained from cultures of Streptomyces natalensis. Structures consists of 26-membered lactone instead of the 38 for Nystatin and Amphotericin B. The 26-membered polyenes cause both K leakage and cell lysis at same concentration. Natamycine suppl

24、ied as a 5% ophthalmic suspension intended for the treatment of fungal conjunctivitis, blepharitis and keratitis.,Natamycin,Natamycin,Azole Antifungal Agents,Azole antifungal agents are the largest class of synthetic antimycotics. About 20 agents on the market today. Some used topically to treat sup

25、erficial dermatophytic and yeast infections. Others used systemically to treat severe fungal infections. Antifungal activity stems from the presence of an aromatic five member heterocyclic, either an imidazole (two nitrogen atoms) or a triazole (three nitrogen atoms),The first members of the class w

26、ere highly substituted imidazoles (clotrimazole, miconazole) were not absorbed orally. Ketoconazole introduced in 1984 was the first effective oral therapy for Candida. Itroconazole and Fluconazole are more potent, less toxic and provide effective oral therapy for many systemic fungal infections. Th

27、ese two are triazoles. Another triazole has been recently introduced (voriconazole). That said, amphotericin B is usually the preferred drug for life threatening systemic fungal infections. It is still the “gold standard”.,Examples of Azole agents,Ketoconazole (KCZ) - fairly broad spectrum, PO antif

28、ungal. Most of the use of this drug for significant fungal infections has been replaced by fluconazole and itraconazole.2) Fluconazole- (FCZ) Oral and IV. It is indicated for candidiasis (oral, esophageal, vaginal) and for Cryptococcus infections including Cryptococcal meningitis. It also is being u

29、sed for other fungal infections. It is used in a low dose (50-100 mg/d) to prevent candidiasis and cryptococcal meningitis in AIDS patients. It is used as a one time stat dose (150 mg) for vaginal candidiasis. It is an expensive drug but has relatively few adverse effects.3) Itraconazole (ICZ) - Ora

30、l and IV, also a suspension. Introduced in late 1992. Is indicated for a number of systemic infections. Also for oral and esophageal candidiasis. Also for dermatophytic infections of the toenail and fingernail (Tinea unguium). It has broad antifungal activity.4) Voriconazole (VCZ)- Oral and IV. Intr

31、oduced in 2002. At present is indicated for invasive Aspergillus and several other serious invasive fungal infections, e.g. Fusarium sp. Taken one hour before or after a meal. Highly bioavailable.,Specific Azole Agents,Ketoconazole - significant inhibitor of several P450 isozymes. Fairly selective f

32、or CYP3A4. Increases levels of a number of drugs taken concurrently. Severe nephrotoxicity with cyclosporine A. Must reduce cyclosporine A dose. Rifampin induces metabolism of ketoconazole and visa versa. Will interact with any drug mainly cleared by CYP3A4.Fluconazole CYP3A4 inhibitor but less pote

33、nt than KCZ. Minor effect on cyclosporin although potential is there. Inhibits CYP2C9 and 2C19 therefore potential interactions with warfarin and phenytoin. Other drugs may show increased levels. Rifampin induces metabolism of FCZ.Itraconazole Inhibits CYP3A4 and CYP2C9 but less potent than KCZ. In

34、high doses should reduce dose of cyclosporin. The potential for elevated levels of other drugs metabolized by CYP3A4 taken concurrently is significant. Rifampin - same as above.Voriconazole similar drug interactions as ICZ.,Drug interactions with Azoles,New azole agent more recently approved,Posacon

35、azole (Schering-Plough)Novel trizole antifungal recently approved for use as an oral suspension to treat invasive fungal infections. Fungistatic against Candida and fungicidal against Asperigillus species. Similar structure to Itraconazole, absorbtion greatly affected by food. Mainly metabolized by

36、phase II glucuronide conjugation and has little interaction with P450 enzymes.,Posoconazole,Nucleoside Antifungals,Orally active antifungal with a very narrow spectrum of activity Flucytosine was synthesized in 1957 as an antitumor agent. It was inactive but it was found to have antifungal activity.

37、 Drug inters fungal cell through active transport on ATPases that normally transport pyrimidines. Once inside cells, fungal cytosine deaminase convert the drug to active 5-fluorouracl (5FU) which is incorporated into RNA causing faulty RNA synthesis. It is also is a strong, non-competitive inhibitor

38、 of thymidylate synthesis interrupting the one carbon pool substrate. Mammalian cells do not contain cytosine deaminase.,Resistance develops rapidly and occurs on many levels e.g. transport into the cell and cytosine deaminase steps. After a few dosing intervals the drug is essentially useless. To a

39、void rapid resistance, combination with Amphotericin B, and the combination is synergistic. It is also synergistic with itraconazole and fluconazole, and interest in these combinations for treatment of systemic Candida infections is increasing. Amphotericin B damaged membranes are thought to allow b

40、etter entry of flucytosine. Used (with Amp. B) for Cryptococcal meningitis, systemic Candida infections, and some other systemic fungal infections. Adverse Effects 1)GI upset - very common.2)Hepatic - 5% have increased transaminases.3)Hematologic - anemia, leukopenia, thrombocytopenia; this is the m

41、ajor complication of therapy and may be due to low levels of 5-FU circulating.4)adverse effects seen when plasma levels reach 100 mcg/ml,Nucleoside Antifungals,Ergosterol Biosynthesis Inhibitors,AllylaminesHave a more limited spectrum of activity than the azoles and are only effective only against d

42、ermatophytes. Employed in treatment of fungal infections of skin and nails,Inhibits squalene epoxidase (not a P450 enzyme) involved in conversion of squalene to squalene-2,3-expoxide decreased squalene-2,3 epoxide leads to decreased lanosterol and ergosterol. This decrease alters the physical-chemic

43、al properties of the membrane resulting in pH imbalance, malfunction of membrane embedded proteins. Inhibition of Squalene epoxidase results in accumulation of squalene which in itself is toxic to fungal cells. May be fungicidal,Terbinafine Lamisil Novartis, 250 mg tabs,Cell wall inhibitors,Echinoca

44、ndins, a group of cyclic peptides with long lipophillic sidechains have been under investigation for a number of years. They interfere with cell wall biosynthesis through inhibition of the enzyme -1,3-glucan synthase. Reduction of in the glucan content weakens the cell wall and leads to rupture of f

45、ungal cells. Some agents made it up to phase III trials only to fail due to formulation problems.,Echinocandins,Micafungin,Caspofungin (parenteral),Anidulafungin,approved for invasive aspergillosis in patients refractory to or intolerant of other therapies . IV use only,Miscellaneous Antifungals,Gri

46、seofulvinAntifungal antibiotic produced from Penicillium griseofulvin. Effects on microtubules to inhibit cell division microsize and ultramicrosizeTherapy must continue until new tissue replaces old diseased tissue. When given orally, plasma-borne griseofulvin becomes incorporated into keratin prec

47、ursor cells and ultimately into keratin which cannot then support fungal growth.Griseofulvin is mainly effective on dermatophytesHeadache is a common adverse effect. May cause aplastic anemia. Being gradually replaced by newer agents.,Undecylenic Acid H2C=CH(CH2)8COOHWidely used as the zinc salt in

48、OTC preparations for topical treatment of infections by dermatophytes. A fungistatic acting through non-specific interaction with components in cell membrane.Can be used in concentrations up to 10% in solution, powder and emulsions. Traditionally used for athletes foot (tinea pedis) although cure ra

49、tes are low.,Ciclopirox A hydroxylated pyridinone used for superficial dermatophytic infections mainly onychomycosis. It caused inhibition of polyvalent cations (Fe+3) and caused inhibition of metallic enzymes in the fungal cell. A new formulation of an 8% lacquer has been recently introduced for tr

50、eating nail infections.,Ciclopirox,Miscellaneous Antifungals,Antifungal Agents (Re-cap),Echinocandins Inhibit fungal cell wall biosynthesis,Griseofulvin Inhibits mitotic spindle formation,All inhibitors of fungal cell wallsa) Other -1,3 glucan synthetase inhibitors Papulacandins glycolipid antifungal produced by Papularia sp.b) Chitin Synthase inhibitors Polyoxins and Nikkomycins nucleoside peptidesc) Mannan binding antifungals Pradimicins and benanomicins,

copyright@ 2008-2019 麦多课文库(www.mydoc123.com)网站版权所有
备案/许可证编号:苏ICP备17064731号-1